Clinical trials: Seizures Disorders
Status Epilepticus
Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan
The purpose of this study is to determine the efficacy, safety and pharmacokinetics of Lorazepam on Japanese patients with Status Epilepticus or Repetitive Status Eplilepticus.
- Trial name
- NCT02239380
- Testing
- Lorazepam
- Where
- 20 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Pfizer
Epilepsy
First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients
The purpose of this study is to examine seizure control and tolerability of Topiramate after either transitioning from previous antiepileptic drug (AED) or adding on to previous AED.
- Trial name
- TEAMS (NCT01627860)
- Testing
- Topiramate add-on therapy, Topiramate monotherapy
- Volunteers
- 55 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Epilepsy, Partial
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
- Trial name
- NCT00355082
- Testing
- lamotrigine, 300 mg/day, lamotrigine, 250 mg/day
- Where
- 103 sites in United States, Argentina and 6 more
- Volunteers
- 226 people
- Sponsor
- GlaxoSmithKline
Hearing Loss, Ear Diseases
Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System
This is a prospective within-subjects repeated-measures study that will enroll 17 users 13 years or older implanted with a HiResolution Bionic Ear System.
- Conditions
- Hearing Loss, Ear Diseases, Hearing Disorders, Otolaryngological Disease
- Trial name
- NCT05034731
- Testing
- Remote Fitting, In-Office Fitting
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Advanced Bionics
Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an effective adjunct therapy in the treatment of refractory partial seizures
- Trial name
- NCT00988429
- Testing
- 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate
- Where
- 162 sites in United States, Argentina and 9 more
- Volunteers
- 653 people
- Sponsor
- Bial - Portela C S.A.
Partial Epilepsy in Children and Adolescents
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
The purpose of this study is to examine the efficacy and safety of Eslicarbazepine acetate (BIA 2-093) when given with other anti-epileptic drugs to treat children with partial seizures whose condition has not been controlled by…
- Trial name
- NCT00988156
- Testing
- Eslicarbazepine acetate (BIA 2-093), Eslicarbazepine acetate
- Where
- 91 sites in Austria, Bosnia and Herzegovina and 19 more
- Volunteers
- 304 people
- Sponsor
- Bial - Portela C S.A.
Brain Injuries, Acute, Brain Injuries, Traumatic
Antiseizure Medication in Seizure Networks at Early Acute Brain Injury
The goal of this clinical trial is to explore the effect of FDA-approved antiseizure drugs in the brain connectivity patterns of severe and moderate acute brain injury patients with suppression of consciousness.
- Conditions
- Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia
- Trial name
- NCT06081283
- Testing
- Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of North Carolina, Chapel Hill
Epilepsy
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.
This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).
- Trial name
- NCT02316847
- Testing
- diazepam nasal spray
- Where
- 33 sites in United States
- Volunteers
- 126 people
- Sponsor
- Acorda Therapeutics
Status Epilepticus
Treatment of Refractory Status Epilepticus
The purpose of this study is to determine whether propofol or barbiturates should be preferred in the treatment of status epilepticus (continuous seizure activity) refractory to 2 standard antiepileptic agents.
- Trial name
- NCT00265616
- Testing
- propofol, thiopental/pentobarbital
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 23 people
- Sponsor
- Brigham and Women's Hospital
Refractory Partial Seizures
A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
The purpose of this trial is to investigate the safety and tolerability of perampanel in long- term treatment in the patients with refractory partial epilepsy (uncontrolled with other anti-epileptic drugs) who completed Week 10…
- Trial name
- NCT00903786
- Testing
- perampanel
- Where
- 9 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy
A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures
A two arm, randomized, double-blind study comparing zonisamide with placebo. The zonisamide arm will consist of 100 subjects and the placebo arm of 50 subjects.
- Trial name
- NCT01546688
- Testing
- Zonisamide at targeted daily doses of 100-500 mg/day
- Where
- 36 sites in Germany, Hungary and 5 more
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Epilepsy
Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.
- Trial name
- NCT01364597
- Testing
- Brivaracetam (BRV)
- Where
- 56 sites in United States, Belgium and 10 more
- Volunteers
- 257 people
- Sponsor
- UCB Pharma SA
Cardiac Arrest
Augmented Multimodal Neurologic Monitoring in High Risk Survivors of Cardiac Arrest
Cardiac arrest is the most common cause of death in the United States and as many as 590,000 Americans suffering a cardiac arrest each year.
- Trial name
- NCT02069353
- Testing
- QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA), Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonathan Elmer
Epilepsy
Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.
- Trial name
- ARTEMIS1 (NCT01390220)
- Testing
- USL261
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 292 people
- Sponsor
- UCB Biopharma S.P.R.L.
Drug-Resistant Epilepsy, Focal-Onset Seizures
Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
The purpose of the study is to evaluate the long-term safety and tolerability of Padsevonil administered at individualized doses as adjunctive treatment for subjects with drug-resistant epilepsy.
- Trial name
- NCT03370120
- Testing
- Padsevonil
- Where
- 156 sites in United States, Australia and 25 more
- Volunteers
- 406 people
- Sponsor
- UCB Biopharma SRL
Epilepsy
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
Evaluating efficacy \& safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy…
- Trial name
- VALOR (NCT02408523)
- Testing
- Lacosamide Tablet, Lasosamide Oral Solution
- Where
- 115 sites in United States, Australia and 20 more
- Volunteers
- 242 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH
Epilepsy
Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures
This is a randomized study designed to compare long-term treatment outcomes in pediatric patients with refractory seizures treated with VNS (Vagus Nerve Stimulation) Therapy versus anti-epileptic drugs (AEDs).
- Trial name
- NCT01118455
- Testing
- Vagus Nerve Stimulation (VNS) Therapy, Anti-Epileptic Drug (AED)
- Where
- 19 sites in Austria, Belgium and 3 more
- Volunteers
- 134 people
- Sponsor
- Cyberonics, Inc.
Refractory Partial Onset Seizures
Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301.
- Trial name
- NCT00448539
- Testing
- Rufinamide
- Where
- 27 sites in United States
- Volunteers
- 286 people
- Sponsor
- Eisai Inc.
Epilepsy
Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures
To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.
- Trial name
- NCT00419393
- Testing
- Keppra XR (Levetiracetam XR)
- Where
- 35 sites in United States, Mexico and 2 more
- Volunteers
- 190 people
- Sponsor
- UCB Pharma